|
Market Closed -
Nasdaq
23:00:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.060 USD | -4.50% |
|
-4.50% | -54.51% |
| 10-26 | Spero Therapeutics, Inc. Announces Executive Changes | CI |
| 08-13 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 61.73 | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -52.98% | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 61.73 | 61.73 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -52.98% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -1.83x | -10.1x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 28.3x | 1.67x | 0.75x | 1.17x | - | 239x | - |
| EV / Revenue | 0x | 0x | 0x | 0x | - | 239x | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | - | -1.68x | -1.12x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.58 | -0.105 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 18.26 | 53.51 | 103.8 | 47.98 | - | 0.258 | - |
| EBITDA | -87.32 | - | - | - | - | - | - |
| EBIT 1 | -87.97 | -42.2 | 21.48 | -73.36 | - | -36.66 | -55 |
| Net income 1 | -89.76 | -46.42 | 22.81 | -68.57 | - | -33.46 | -51.5 |
| Net Debt | -146.4 | - | - | - | - | - | - |
| Reference price 2 | 16.010 | 1.730 | 1.470 | 1.030 | 2.330 | 1.060 | 1.060 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 58,235 | - |
| Announcement Date | 3/31/22 A | 3/30/23 A | 3/13/24 A | 3/27/25 A | 3/26/26 A | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83x | - | - | - | 61.73M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 16.14x | 28.02x | 6.57x | 0.34% | 39.44B | |
| Weighted average by Cap. | 22.09x | 26.34x | 10.94x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
